Morepen Laboratories Limited (NSE:MOREPENLAB)
47.20
+0.56 (1.20%)
Aug 13, 2025, 3:30 PM IST
Morepen Laboratories Revenue
Morepen Laboratories had revenue of 4.30B INR in the quarter ending June 30, 2025, a decrease of -6.32%. This brings the company's revenue in the last twelve months to 18.01B, up 2.50% year-over-year. In the fiscal year ending March 31, 2025, Morepen Laboratories had annual revenue of 18.30B with 7.52% growth.
Revenue (ttm)
18.01B
Revenue Growth
+2.50%
P/S Ratio
1.42
Revenue / Employee
8.37M
Employees
2,152
Market Cap
25.58B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 18.30B | 1.28B | 7.52% |
Mar 31, 2024 | 17.02B | 2.80B | 19.68% |
Mar 31, 2023 | 14.22B | -1.34B | -8.60% |
Mar 31, 2022 | 15.56B | 3.58B | 29.87% |
Mar 31, 2021 | 11.98B | 3.40B | 39.57% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 232.42B |
Fortis Healthcare | 80.94B |
Aurobindo Pharma | 320.25B |
Morepen Laboratories News
- 7 days ago - Morepen Laboratories shares drop 4% as Q1 net profit drops 68.5% YoY to Rs 11.4 crore - Business Upturn
- 7 days ago - Morepen Laboratories Q1 Results: Net profit plunges 68% YoY to Rs 11.4 crore, revenue down 6.6% YoY - Business Upturn
- 2 months ago - Morepen Laboratories secures Rs 50 crore loan facility from Qatar National Bank - Business Upturn
- 3 months ago - Morepen Laboratories share price drops 3% as Q4 Ebitda falls 12.6% to Rs 42.3 crore - Business Upturn
- 3 months ago - Morepen Laboratories receives SEC clearance for Resmetirom bioequivalence studies - Business Upturn
- 3 months ago - Morepen Labs shares rally 7% today on this major update – Know More - Business Upturn
- 3 months ago - Morepen Labs launches 4 new drugs in April 2025, eyes Rs 1,000 crore formulation business in 5 years - Business Upturn
- 4 months ago - Morepen Laboratories to add 1,000 medical representatives in major expansion drive - Business Upturn